Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $75.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.14M
Market Cap
$5.95B
Enterprise Value$4.89B
Total Cash (Recent Filing)$149.75M
Total Debt (Recent Filing)$76.00K
Price to Earnings (P/E)45.7
Beta1.12
Next Earnings
Apr 30, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding105,503,430
10 Day Avg. Volume1,539,684
30 Day Avg. Volume1,142,959
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)N/A
Price to Sales (P/S)8.66
Price to Cash Flow (P/CF)24.60
P/FCF Ratio24.70
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda35.55
Forecast
1Y Price Target
$109.50Price Target Upside94.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Corcept Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
FDA Approval ProcessThe FDA has accepted the NDA submission for relacorilant in Cushing's for filing, moving it one step closer to approval.
Market OpportunitiesExpectations are high for a positive Phase III readout from ROSELLA in platinum-resistant ovarian cancer, potentially creating a second blockbuster opportunity for Corcept.
Bears Say
Operational ChallengesThe 4Q24 revenue for Korlym experienced a slight decrease due to operational challenges with the company's pharmacy partner.
---
Ownership Overview
15.21% Insiders
17.97% Mutual Funds
16.83% Other Institutional Investors
25.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $20.84 and its highest was $75.00 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $5.95B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 49 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 26, 2025. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.426 by -$0.166.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.15.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,503,430 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.26 in its last earnings report, missing expectations of $0.426. Following the earnings report the stock price went down -5.555%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.50 (94.15% Upside)
$109.50 (94.15% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.57%
12-Months-Change
Fundamentals
Return on Equity
23.55%
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Corcept Therapeutics demonstrated strong financial performance with significant revenue and net income growth. The company made substantial progress in drug development, notably with relacorilant for hypercortisolism and potential cancer treatments. However, they faced operational challenges affecting revenue and a legal setback with Teva. Despite these issues, the overall outlook remains positive due to strategic advancements and strong financials.Read More>---
CORT Stock 12 Month Forecast
Average Price Target
$109.50
▲(94.15% Upside)
Technical Analysis
Amgen
―
Neurocrine
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering CORT
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+56.91%
reiterated a buy rating 13 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +56.91% per trade.
---